Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221309 · ClinicalTrials.gov registry record
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
A clinical trial of HCV and PrEP, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- 198
- Enrollment target
- 2
- Study locations
NCT03221309: Active study of HCV and PrEP, sponsored by University of Maryland, Baltimore.
NCT03221309 is a study of HCV and PrEP that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 198 participants, above the 174-participant average among 8 other HCV trials with a reported enrollment target (14% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03221309, a study of HCV and PrEP, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- 198 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label, non-randomized, observational pilot study to evaluate a model of care for treatment of hepatitis C in people with ongoing injection drug use. Participants will be treated with direct-acting antivirals (DAA) as per standard of care and will concomittantly be offered pre-exposure prophylaxis for HIV prevention and buprenorphine for treatment of opioid use disorder when clinically indicated.
Primary Outcome
Undetectable HCV viral load 12 weeks after the end of treatment
Conditions Studied
Interventions
- OTHER Evaluate model of care for HCV-infected adults with on-going opioid misuse
Study Locations (2)
District of Columbia
- HIPS - Washington D.C.
Maryland
- University of Maryland Drug Treatment Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2026-01 |
What the registry record for NCT03221309 still lists
NCT03221309 is an observational study that tracks outcomes without assigning an intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, above the 174-participant average among 8 other HCV trials with a reported enrollment target (14% higher).
The record links to 3 conditions, with HCV appearing as the primary indexed condition, and to 1 intervention - of which Evaluate model of care for HCV-infected adults with on-going opioid misuse is the first listed.
NCT03221309 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03221309 about?
NCT03221309 is a clinical study titled "Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior". This is an open label, non-randomized, observational pilot study to evaluate a model of care for treatment of hepatitis C in people with ongoing injection drug use. Participants will be treated with direct-acting antivirals (DAA) as per standard of care and will concomittantly be offered pre-exposur...
What is the current status of trial NCT03221309?
This trial is currently active not recruiting. The enrollment target is 198 participants. The study started on 2017-05-01. Estimated completion is 2026-01.
What conditions does trial NCT03221309 study?
This clinical trial studies the following conditions: HCV, PrEP, Buprenorphine.
What interventions are being tested in trial NCT03221309?
The interventions under investigation include: Evaluate model of care for HCV-infected adults with on-going opioid misuse (OTHER).
Who is sponsoring clinical trial NCT03221309?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03221309 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03221309's enrollment target sits among peer trials
198 4th of 8 higher than 5 of 8 other HCV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HCV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
RECRUITING · NA
-
A Setting Focus Overdose Prevention Intervention
RECRUITING · NA
-
Appalachian Partnership to Reduce Disparities (Aim 2)
RECRUITING · NA
-
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
ACTIVE NOT RECRUITING · NA
-
Integrated HIV Prevention and HCV Care for PWID
ACTIVE NOT RECRUITING · NA
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI